Fulcrum Capital LLC Grows Stake in Edwards Lifesciences Co. (NYSE:EW)

Fulcrum Capital LLC raised its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 3.5% in the fourth quarter, HoldingsChannel reports. The firm owned 122,012 shares of the medical research company’s stock after acquiring an additional 4,107 shares during the period. Edwards Lifesciences comprises about 1.9% of Fulcrum Capital LLC’s investment portfolio, making the stock its 17th largest holding. Fulcrum Capital LLC’s holdings in Edwards Lifesciences were worth $9,033,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Nordea Investment Management AB raised its position in Edwards Lifesciences by 34.6% during the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock valued at $301,355,000 after purchasing an additional 1,043,484 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Edwards Lifesciences by 9.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 478,418 shares of the medical research company’s stock worth $31,571,000 after acquiring an additional 40,348 shares in the last quarter. AIA Group Ltd raised its position in shares of Edwards Lifesciences by 91.7% in the 3rd quarter. AIA Group Ltd now owns 749,524 shares of the medical research company’s stock worth $49,461,000 after acquiring an additional 358,556 shares in the last quarter. RiverPark Advisors LLC raised its position in shares of Edwards Lifesciences by 58.1% in the 3rd quarter. RiverPark Advisors LLC now owns 20,639 shares of the medical research company’s stock worth $1,362,000 after acquiring an additional 7,583 shares in the last quarter. Finally, Banque Cantonale Vaudoise raised its position in shares of Edwards Lifesciences by 46.9% in the 3rd quarter. Banque Cantonale Vaudoise now owns 81,111 shares of the medical research company’s stock worth $5,353,000 after acquiring an additional 25,886 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on EW shares. Jefferies Financial Group lowered Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their price target for the stock from $85.00 to $70.00 in a research report on Wednesday, September 18th. Stifel Nicolaus boosted their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the stock a “hold” rating in a research note on Thursday, December 5th. Piper Sandler dropped their target price on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Finally, Robert W. Baird dropped their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Sixteen investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $79.40.

Edwards Lifesciences Price Performance

NYSE EW traded down $1.64 during trading hours on Monday, reaching $71.78. The company’s stock had a trading volume of 3,397,817 shares, compared to its average volume of 3,838,476. The firm has a market capitalization of $42.34 billion, a price-to-earnings ratio of 10.36, a P/E/G ratio of 3.61 and a beta of 1.11. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company’s 50-day moving average is $71.64 and its two-hundred day moving average is $71.92.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.67. The company had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.59 EPS. On average, equities analysts predict that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 37,500 shares of company stock valued at $2,508,350 over the last quarter. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.